Updates from ASCO 2025 explored PARP inhibitors, PSA as a prognostic biomarker and the function of ctDNA in personalizing genitourinary most cancers care.
On the 2025 ASCO Annual Assembly, there was a plethora of insights shared throughout the realm of oncology, together with genitourinary (GU) cancers of the prostate and bladder. These updates proceed to push the envelope of care that suppliers might give their sufferers based mostly on new commonplace of care and remedy updates.
To completely perceive the practice-changing updates to have come out of the assembly, Dr. Joshua Ok. Sabari sat down with Dr. Daniel V. Araujo to additional delve into these insights.
Sabari is the editor in chief of CURE, in addition to an assistant professor within the Division of Drugs at NYU Grossman Faculty of Drugs and director of Excessive Reliability Group Initiatives at Perlmutter Most cancers Middle. Araujo serves as a medical oncologist on the College of Florida Well being (UF) Well being.
Learn on to study extra from their dialog and assembly insights from ASCO 2025 on genitourinary cancers beneath!
Sabari: Hiya and welcome. My title is Dr. Joshua Sabari. I am a thoracic medical oncologist at NYU Langone Well being Perlmutter Most cancers Middle, in New York, and I am excited to be joined by my colleague, Dr. Daniel Araujo. So, Dr. Araujo, please introduce your self.
Araujo: Thanks a lot, Dr. Sabari. My title is Dr. Daniel Araujo. I am a genitourinary medical oncologist on the College of Florida Gainesville. It is a pleasure to be right here.
Sabari: Daniel, welcome. I am additionally the editor in chief for CURE, and we’re excited so that you can give us a few of the ASCO updates within the genitourinary, of GU, area. Stroll us by way of what a few of the thrilling takeaways from this ASCO 2025.
Araujo: Thanks rather a lot. ASCO, as you realize, is at all times an ideal assembly to attend, the place quite a few abstracts are introduced, and knowledge is consolidated. This yr, significantly in genitourinary cancers, we noticed some fascinating developments. Maybe essentially the most practice-changing summary could be the AMPLITUDE trial.
AMPLITUDE was a randomized managed trial investigating the function of Zejula (niraparib), which is a PARP inhibitor, in sufferers with metastatic hormone-sensitive prostate most cancers. PARP inhibitors have already got a longtime function in sufferers with castration-resistant prostate most cancers, and now, for the primary time, they’re being examined within the hormone-sensitive setting.
Basically, sufferers with homologous recombination restore (HRR) gene defects had been randomized to obtain Akeega (niraparib plus abiraterone acetate [Zytiga]) versus abiraterone [alone.] This inhabitants represents about 30% of all sufferers with prostate most cancers, so it is a minority, however this group is thought for having extra aggressive illness with worse outcomes. Basically, the addition of Zejula to Zytiga was capable of prolong progression-free survival, particularly for sufferers with BRCA mutations.
This knowledge will possible be assessed by the FDA and different regulators. Different trials with totally different molecules in addition to Zejula are being examined in the identical area to see if this can be a class impact, and it is most likely akin to what we see within the castration-resistant setting.
Sabari: Daniel, [PARP inhibitors] are an thrilling [area of interest]. Now we have seen approvals [of these agents across cancer types]. What are a few of the unintended effects that sufferers ought to learn about which are related to PARP inhibitors?
Araujo: That is an ideal query. PARP inhibitors have some class results, which primarily contain toxicity to the bone marrow, resulting in circumstances like anemia, neutropenia, and thrombocytopenia. Subsequently, earlier than every cycle, we normally repeat blood work to make sure that sufferers’ blood counts are inside the reference vary. Generally, we’ve got to implement dose reductions to handle these results. Different potential unintended effects embrace fatigue and typically diarrhea. For some sufferers, we have to regulate the dose accordingly.
Sabari: Very thrilling replace, I utterly agree with you. Properly, what else is thrilling within the genitourinary area at ASCO 2025 this yr?
Araujo: We noticed some fascinating prognostic knowledge, which, whereas maybe not instantly treatment-changing, supplies some vital insights. For instance, in a big database of prostate cancers handled with ARPIs (androgen receptor pathway inhibitors) and ADT (androgen deprivation remedy) — which is basically the usual of look after sufferers with hormone-sensitive prostate most cancers — we noticed that sufferers who achieved a PSA of lower than 0.2 at six months since remedy initiation have an excellent prognosis.
That is fascinating as a result of it presents a state of affairs the place you would doubtlessly take a look at de-escalation methods for sufferers who obtain that PSA lower than 0.2. Conversely, you would additionally take a look at escalation methods for sufferers who didn’t obtain that focus on, maybe intensifying remedy to try to obtain that. It is a very clear outcome-based biomarker of prognosis. There are already some trials investigating, for instance, the function of including chemotherapy to the remedy routine for sufferers who haven’t achieved a PSA lower than 0.2.
Sabari: We all know how vital biomarkers are throughout all stable tumors, and I agree with you, this might turn out to be a vital biomarker to permit us to escalate or doubtlessly deescalate remedy into the longer term. Every other thrilling insights from ASCO earlier than wrapping up?
Araujo: One other know-how that’s changing into widespread in nearly all cancers is circulating tumor DNA (ctDNA). This was additionally introduced at ASCO, demonstrating its prognostic impact in sufferers with muscle-invasive bladder most cancers. We all know that sufferers with constructive ctDNA earlier than chemotherapy within the neoadjuvant setting have a worse prognosis and a decrease probability of reaching a pathologic full response to remedy. This basically helps establish a bunch of sufferers with a poorer prognosis. That is vital as a result of it could actually assist us goal these particular teams to accentuate remedy, maybe with extra aggressive approaches, and attempt to get the illness beneath management.
The other can also be true: we are able to ultimately de-escalate remedy for sufferers with adverse ctDNA upfront. So, the extra we all know concerning the habits and biology of the illness, the extra precisely we are able to make use of the proper remedy for the proper affected person.
Sabari: Yeah, I could not agree extra. Right here, we’re seeing in bladder most cancers, utilization of ctDNA, as you talked about, as a molecular biomarker to assist doubtlessly information remedy. So very thrilling updates. Dr Araujo, it is a pleasure to fulfill you. A pleasure to have this dialogue with you, and thanks to the CURE readership and listeners to your consideration. Daniel, I sit up for speaking once more quickly.
Araujo: Thanks a lot. It was a pleasure to be right here.
Transcript has been edited for readability and conciseness.
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
